Puff Wealth Management LLC Takes $464,000 Position in Abbott Laboratories $ABT

Puff Wealth Management LLC purchased a new position in Abbott Laboratories (NYSE:ABT) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 5,109 shares of the healthcare product maker’s stock, valued at approximately $464,000.

A number of other institutional investors also recently added to or reduced their stakes in ABT. LifeGoal Investments LLC acquired a new stake in shares of Abbott Laboratories during the 2nd quarter worth about $206,000. Cooper Financial Group boosted its position in Abbott Laboratories by 24.9% in the second quarter. Cooper Financial Group now owns 6,790 shares of the healthcare product maker’s stock valued at $616,000 after buying an additional 1,353 shares in the last quarter. Renaissance Investment Group LLC grew its stake in Abbott Laboratories by 2.8% during the second quarter. Renaissance Investment Group LLC now owns 9,663 shares of the healthcare product maker’s stock worth $877,000 after buying an additional 262 shares during the last quarter. Attessa Capital LLC increased its holdings in shares of Abbott Laboratories by 28.7% during the second quarter. Attessa Capital LLC now owns 3,359 shares of the healthcare product maker’s stock worth $305,000 after buying an additional 749 shares in the last quarter. Finally, Elmwood Wealth Management Inc. increased its holdings in shares of Abbott Laboratories by 8.8% during the second quarter. Elmwood Wealth Management Inc. now owns 16,430 shares of the healthcare product maker’s stock worth $1,491,000 after buying an additional 1,331 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Diagnostics expansion strengthens growth outlook: Abbott is broadening its Diagnostics growth base through its Exact Sciences relationship and oncology testing expansion. Gains in cancer diagnostics and resilient routine testing are helping offset weaker respiratory-related demand, potentially making growth less dependent on COVID and respiratory testing. Here’s How ABT Broadens Diagnostics Growth Base With Oncology Expansion
• Positive Sentiment: Analysts remain bullish: Although ABT has lagged the broader market over the past year, Wall Street analysts continue to view the stock favorably and see further upside potential based on Abbott’s diversified healthcare portfolio and earnings durability. Abbott Stock: Is Wall Street Bullish or Bearish?
• Positive Sentiment: Reliable-growth investment case: An investor letter from Matrix Asset Advisors presents Abbott as a compelling long-term healthcare holding, emphasizing its dependable growth profile and diversified end markets. Broader nutritional-market growth could also support Abbott’s nutrition business over time. What Makes Abbott Laboratories a Compelling Investment Opportunity Global Nutritional Market Outlook
• Neutral Sentiment: Value debate remains: Comparisons with Envista (NVST) focus on which medical-products stock offers better value. The coverage may prompt investors to weigh Abbott’s premium valuation against its stronger diversification and consistency, but it does not represent a new company-specific catalyst. NVST vs. ABT: Which Stock Is the Better Value Option?
• Neutral Sentiment: Competitive backdrop: Analysts’ discussion of Abbott alongside other healthcare companies provides sector context, but no major change to Abbott’s outlook is indicated. Boston Scientific’s reduced 2026 guidance could be relatively favorable for Abbott if investors rotate toward companies with steadier execution, though it also underscores competitive pressures in medical devices. Analysts Offer Insights on Healthcare Companies

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Citigroup upped their target price on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. Wells Fargo & Company increased their price target on shares of Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. Bank of America lowered their price objective on shares of Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Piper Sandler reiterated an “overweight” rating and issued a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Finally, The Goldman Sachs Group lowered their price objective on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research report on Wednesday, May 27th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.17.

Abbott Laboratories Trading Down 0.1%

Shares of ABT stock opened at $107.81 on Friday. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The company has a market capitalization of $186.56 billion, a PE ratio of 34.89, a price-to-earnings-growth ratio of 2.09 and a beta of 0.59. The firm has a 50 day moving average price of $95.51 and a two-hundred day moving average price of $100.03. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter last year, the firm earned $1.26 earnings per share. The company’s revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be given a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s payout ratio is presently 81.55%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.